Biotechnology M&A » By The Online Investor Staff, updated Sat., Aug. 13, 12:01 PM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #40 of 83 |
Slide #40. StemCells, Inc. — Seminal Neural Stem Cell Patent Portfolio
Acquirer:
StemCells, Inc. (NYSE:STEM)
Acquiree:
Seminal Neural Stem Cell Patent Portfolio
Details:
StemCells, Inc. (Nasdaq:STEM) today announced the acquisition of a portfolio of issued US and Canadian patents to which it had previously held an exclusive worldwide license. The portfolio broadly claims the manufacture and proliferation of purified populations of human neural stem cells and their use as therapeutics and as tools for drug discovery. The acquisition relieves the Company of all milestone and royalty obligations under the license agreements for products claimed by the patents, such as products derived from the Company's proprietary HuCNS-SC cells (purified human neural stem cells). The patents arose from the groundbreaking research of Samuel Weiss, Ph.D., and Brent Reynolds, Ph.D., while at the University of Calgary. As consideration for the portfolio, the Company will issue 139,548 shares of common stock to Neurospheres Holdings Ltd., an intellectual property holding company affiliated with the University of Calgary.
Stem is a newly formed blank check company established for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Co.'s focus is on identifying opportunities in several trends of potential interest including renewable energy generation, bio fuels, carbon capture, hydrogen technologies, fuel cells, electric vehicle infrastructure, transportation, mobility, energy transportation and storage and other Energy Transition technologies.
STEM SEC Filing Email Alerts Service
Open the STEM Page at The Online Investor »
|
|||||||||||||||||||||
Open the STEM Page at The Online Investor (in a new window) »
 Free STEM Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Buy (3.00 out of 4) 17th percentile
(ranked lower than approx. 83% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
